Unlearn

Unlearn is an AI/ML-focused biotech company pioneering the use of digital twin technology in clinical trials. Its core platform generates AI-powered forecasts of patient outcomes to serve as enhanced control arms, a methodology qualified by the European Medicines Agency (EMA) and aligned with FDA guidance. By integrating this technology with its upstream trial design workspace, TrialPioneer, Unlearn offers a unified solution to improve trial planning, reduce costs, and shorten development timelines. The company is actively partnering with leading biopharma firms across neuroscience, immunology, and metabolic diseases to implement its technology in active studies.

AI-powered platform that generates digital twins (forecasts of control outcomes) for clinical trial participants and provides an integrated workspace (TrialPioneer) for upstream trial design, planning, and analysis.

Unlearn operates in the competitive space of AI for clinical development. It faces competition from other startups focused on synthetic control arms and trial optimization (e.g., Aetion, Novadiscovery), as well as from large Contract Research Organizations (CROs) like IQVIA and Medpace that are building internal AI/ML groups. Its key differentiator is its specific regulatory qualifications for its digital twin methodology in neurology.